NAD+
β-Nicotinamide adenine dinucleotide · Research-grade reference material
Identity
- Molecular formula
- C21H27N7O14P2
- Molecular weight
- 663.43 g/mol
- CAS number
- 53-84-9
Research Background
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, central to redox reactions in glycolysis, the citric acid cycle, and oxidative phosphorylation. Unlike its precursors NMN and NR, NAD+ itself is a larger, less cell-membrane-permeable molecule, a relevant consideration for research protocol design.
NAD+ levels decline measurably with age across human tissue types, a pattern documented since at least the early 2010s and now central to a wide body of aging and metabolism research (Massudi et al.). Because NAD+ can’t simply be absorbed intact by cells in the way its smaller precursors can, much of the research field has focused on NMN and NR as delivery routes, while NAD+ itself remains studied directly in cell and animal models, particularly around sirtuin and PARP enzyme activity, both NAD+-consuming processes tied to DNA repair and cellular stress response (Verdin).
Lab-tested research material
Mechanism
NAD+ serves as a substrate, not just a catalyst, for two major enzyme families: sirtuins (SIRT1-7), involved in metabolic regulation and stress resistance, and PARPs, involved in DNA damage repair. Both classes consume NAD+ directly, meaning cellular NAD+ availability places a hard ceiling on how much sirtuin and PARP activity a cell can sustain (Verdin). This substrate relationship is the basis for most current research into restoring youthful NAD+ levels as a lever on cellular repair and metabolic function.
NAD⁺ is not a novel research compound — it is fundamental, well-characterized cellular biochemistry described since the early 20th century. Contemporary research interest centres on the observation that tissue NAD⁺ concentrations decline with age, and on whether raising them alters aging-associated outcomes.
Redox cofactor. The NAD⁺/NADH couple carries electrons through glycolysis, the TCA cycle and oxidative phosphorylation — central to ATP production.
Sirtuin substrate. Required by the SIRT1–SIRT7 deacylases that regulate gene expression and stress responses.
PARP substrate. Consumed by poly(ADP-ribose) polymerases during DNA strand-break repair.
CD38 and turnover. NAD⁺-consuming enzymes contribute to the age-associated decline in tissue NAD⁺.
Biosynthesis. Generated via the salvage pathway (from nicotinamide), the Preiss-Handler pathway (from nicotinic acid), and de novo from tryptophan via kynurenine.
Established biochemical roles of NAD⁺ in cellular metabolism. Schematic. These are textbook enzymology, distinct from claims about supplementation outcomes.
State of the Evidence
Research Evidence: based on 3 sources cited, most recent 2018. Regulatory Status: Not approved by the FDA as a drug for any indication. Availability Status: Research Only.
NAD+ decline with age is well-documented across human tissue studies. Whether restoring NAD+ levels directly translates to slower aging or meaningfully improved health outcomes in humans is a much earlier and unsettled question; most of the mechanistic and interventional research to date is in cell culture and animal models, or uses smaller precursor molecules (NMN, NR) rather than NAD+ itself.
1. Human tissue study — “Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue,” PLOS ONE, 2012. PMID 22848760
2. Review — “NAD+ in Aging, Metabolism, and Neurodegeneration,” Science, 2015. DOI 10.1126/science.aac4854
3. Review — “NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR,” Cell Metabolism, 2018. DOI 10.1016/j.cmet.2017.11.002
What the Literature Supports — and What It Doesn’t
NAD⁺ biochemistry is settled science. The contested question is entirely different: whether raising NAD⁺ produces functional benefit. Two distinctions are essential and are frequently blurred in this category.
Evidence at a glance
Most human data concerns precursors, not NAD⁺ itself. The clinical literature is dominated by oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Parenteral NAD⁺ administration is far less studied.
Target engagement is the one consistent finding. A 2026 PRISMA-guided systematic review identified 113 eligible studies (33 human intervention, 28 of them randomized; 80 rodent) and found oral NR and NMN consistently raised circulating and cellular NAD-related metabolites.
Raising blood NAD⁺ is not the same as clinical benefit. Whether increased levels translate into meaningful functional improvement in the tissues relevant to aging remains the open controversy.
Rodent effects were inconsistent across endpoints. The same review noted improvements in metabolic, mitochondrial and inflammatory outcomes varied by model and endpoint.
Appropriate characterization: a fundamental coenzyme with unambiguous, textbook biochemical function; supplementation research reliably demonstrates target engagement with precursors, while functional and clinical outcomes remain unestablished.
Regulatory & status notes
Selected references
- 1. NAD⁺ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence (113 studies, 2010–2025). Ageing Res Rev. 2026.
- 2. Yang et al. An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of NMN and NR. Food Frontiers. 2025.
- 3. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. (PMC10721522)
- 4. Improved Physical Performance Parameters in Patients Taking NMN: A Systematic Review of RCTs (10 studies, n=437). (PMC11365583)
Safety Information
Research-use compound with limited human data. Evidence strength varies — see the Evidence section above.
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician. For research and educational purposes only, not for human or veterinary use.
Related Compounds
For research and educational purposes only. Not for human or veterinary use.